By PPN News Staff
The FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis), a targeted radioligand therapy, for patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy.
Lu 177 vipivotide tetraxetan, formerly Lu-PSMA-617, combines a ligand, which binds to target cells, with a radioisotope that